Profile for Lifevantage Corporation (LXRX)
« Back to company indexLXRX Chatter Timeline
Stock Ticker for LXRX
Most Active Tweeters for LXRX
| User | Tweets |
|---|---|
| @DrSManian | 7 |
| @Flashtrading | 6 |
| @MarketNotes17 | 6 |
| @Datamonitor_KMS | 5 |
| @CFinancialNews | 5 |
Recent Tweets for LXRX
 |
@IRAMarketReport Lexicon Pharmaceuticals $LXRX Earns Daily Coverage Optimism Rating of 0.13 https://t.co/fyLzfa38RA September 23rd 2017, 5:09pm |
 |
@chaffeybreeze Lexicon Pharmaceuticals $LXRX Earns Daily Coverage Optimism Rating of 0.13 https://t.co/FZ83H3uW2X September 23rd 2017, 5:09pm |
 |
@emq_news Lexicon Pharmaceuticals, Inc. $LXRX Stake Held by Ulys L.L.C. https://t.co/HAAfXqxDpw September 23rd 2017, 12:09pm |
 |
@TheMarketsDaily XBiotech $XBIT versus Lexicon Pharmaceuticals $LXRX Head-To-Head Contrast https://t.co/ZubuBUFe9C September 22nd 2017, 9:09pm |
 |
@finboxio Insider Buy: Lonnel Coats (Insider) bought $376K worth of $LXRX. Yup... stock's trading @ nice discount… https://t.co/1aryJLDiYb September 22nd 2017, 1:09pm |
 |
@Datamonitor_KMS @odibro Thought you might be interested in checking out our discussion on $LXRX's sotagliflozin starts at (0:30) https://t.co/3w1CAdD80w September 22nd 2017, 11:09am |
|
@Datamonitor_KMS @DrSManian Thought you might be interested in checking out our discussion on $LXRX's sotagliflozin starts at (0:30) https://t.co/3w1CAdD80w September 22nd 2017, 11:09am |
|
@Datamonitor_KMS @StocksInMyBlood Thought you might be interested in checking out our discussion on $LXRX's sotagliflozin starts at… https://t.co/9tatI8SX7H September 22nd 2017, 11:09am |
|
@Datamonitor_KMS @sheltonwillia1 Thought you might be interested in checking out our discussion of $LXRX (starts at 0:30) https://t.co/3w1CAdD80w September 22nd 2017, 11:09am |
|
@finboxio While stock's at 66% of 52week high, Lexicon Pharmaceuticals, Inc. $LXRX valuation shows upside… https://t.co/Gean7rBOAT September 22nd 2017, 7:09am |
 |
@PalafoxPatricia $LXRX with all the ingredients 4 a great trade/long term. It has a very bullish weekly chart, excellent news insiders buying. #readytogo September 21st 2017, 3:09pm |
 |
@tymorapro $LXRX: Exc 1DyHIGH=12.74, hits:1, ch:+1.2%, 3phNewHi+, AtgPivH4, 15:3Accel+, tf:0111111, medFlt:43M, HiPctSht[36%:11d], DyVol:96T:0.2x:0.1x September 21st 2017, 12:09pm |
|
@IRAMarketReport Lexicon Pharmaceuticals, Inc. $LXRX Insider Acquires $376,200.00 in Stock https://t.co/sAsP7d3Lio September 21st 2017, 6:09am |
|
@chaffeybreeze Lexicon Pharmaceuticals, Inc. $LXRX Insider Acquires $376,200.00 in Stock https://t.co/aV93HSiYxY September 21st 2017, 6:09am |
|
@emq_news Analysts Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Post Quarterly Sales of $33.98 Million https://t.co/FeIc4zajEz September 21st 2017, 5:09am |
 |
@TickerReport Analysts Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Post Quarterly Sales of $33.98 Million https://t.co/YcUkuI7Mci September 21st 2017, 5:09am |
|
@TickerReport Analysts Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Post Quarterly Sales of $33.98 Million https://t.co/BAOjW968iJ September 21st 2017, 5:09am |
 |
@intercooleronli Analysts Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Post Quarterly Sales of $33.98 Million https://t.co/l2qW3dYLgy September 21st 2017, 5:09am |
 |
@CFinancialNews Analysts Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Post Quarterly Sales of $33.98 Million https://t.co/LU8kvEwhCr September 21st 2017, 5:09am |
 |
@ZolmaxNews $LXRX - Lexicon Pharmaceuticals, Inc. #LXRX Earns Buy Rating from Needham & Company LLC https://t.co/p4J8Til4Cn September 21st 2017, 1:09am |
|
@ZolmaxNews Lexicon Pharmaceuticals, Inc. $LXRX Earns Buy Rating from Needham & Company LLC https://t.co/7X34SiUbGT September 21st 2017, 1:09am |
|
@ZolmaxNews Sam L. Barker Acquires 1,000 Shares of Lexicon Pharmaceuticals, Inc. $LXRX Stock https://t.co/CkwM7jmkrD September 20th 2017, 6:09am |
 |
@dakotafinancial Lexicon Pharmaceuticals’ $LXRX “Buy” Rating Reiterated at Needham & Company LLC https://t.co/1BS4oyMudj September 20th 2017, 6:09am |
 |
@TranscriptDaily Lonnel Coats Acquires 30,000 Shares of Lexicon Pharmaceuticals, Inc. $LXRX Stock https://t.co/aCj0bhdQqW September 20th 2017, 5:09am |
|
@biostockfan RT @BioRunUp: $LXRX European Commission Approves XERMELO® For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin… September 19th 2017, 5:09pm |
|
@intercooleronli Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.35 Per Share https://t.co/HfUa0uX35J September 19th 2017, 4:09pm |
 |
@WatchlistN Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.35 Per Share https://t.co/uo6XgKuL6b September 19th 2017, 4:09pm |
|
@CFinancialNews Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.35 Per Share https://t.co/Z4jpBGaNLe September 19th 2017, 4:09pm |
 |
@MaisaCorp $LXRX Gets Regulatory OK on Xermelo for Carcinoid Syndrome Diarrhea in Europe September 19th 2017, 3:09pm |
 |
@TraderJill77 $LXRX - presents for Cantor on September 25th. I move ahead very cautiously. Somewhat concerned over AEs like acidosis. September 19th 2017, 3:09pm |
 |
@realmaciej RT @odibro: $LXRX EC Approves XERMELO® For The Treatment Of Carcinoid Syndrome Diarrhea In Combo With Somatostatin Analog Therapy September 19th 2017, 2:09pm |
 |
@MarketNotes17 RT @DrSManian: $LXRX look for a red green move and a big #squeeze Insider buys and now ++ EC approval for Carcinoid. September 19th 2017, 2:09pm |
 |
@MomoTrader007 $LXRX what's going on with this lepricon stock ? September 19th 2017, 1:09pm |
|
@TraderJill77 $LXRX - With surface DD it looks like the stock was unjustly punished, thus, its fall from grace. I took a small position to see. September 19th 2017, 1:09pm |
 |
@sheltonwillia1 $LXRX Out flat after commissions, expected more run from this news. #stocks #trading September 19th 2017, 1:09pm |
 |
@SwingTradeBot Recent $LXRX technical alerts: Lower Bollinger Band Walk plus 7 more alerts... https://t.co/NdZ3NUTw8E September 19th 2017, 1:09pm |
 |
@pharma_sector BRIEF-#Lexicon Pharmaceuticals gets European Commission's approval for Xermelo. Read more: https://t.co/juKpyYgDzg $LXRX September 19th 2017, 1:09pm |
 |
@biotech_sector BRIEF-#Lexicon Pharmaceuticals gets European Commission's approval for Xermelo. Read more: https://t.co/Pns7J0B5pe $LXRX September 19th 2017, 1:09pm |
|
@StocksInMyBlood $JNUG $LXRX both look ready to turn up September 19th 2017, 1:09pm |
|
@TraderJill77 $LXRX - Just approved in Europe. This could bounce nicely in the next couple of days, but I have done almost zero research. Worth a look. September 19th 2017, 1:09pm |
 |
@DrSManian $LXRX look for a red green move and a big #squeeze Insider buys and now ++ EC approval for Carcinoid. September 19th 2017, 12:09pm |
 |
@SEEKINGALPHA_FS Ipsen's Xermelo OK'd in Europe for carcinoid syndrome diarrhea; shares ahead 5% https://t.co/MQKgQR1w7L $IPSEY $LXRX September 19th 2017, 12:09pm |
 |
@MarketCurrents Ipsen's Xermelo OK'd in Europe for carcinoid syndrome diarrhea; shares ahead 5% https://t.co/Z7Y7sdxXmX $IPSEY $LXRX September 19th 2017, 12:09pm |
 |
@odibro $LXRX EC Approves XERMELO® For The Treatment Of Carcinoid Syndrome Diarrhea In Combo With Somatostatin Analog Therapy September 19th 2017, 12:09pm |
 |
@BioRunUp $LXRX European Commission Approves XERMELO® For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy September 19th 2017, 12:09pm |
 |
@WizAtWallSt Breaking: $LXRX European Commission Approves XERMELO for treatment of Carcinoid Syndrome Diarrhea September 19th 2017, 12:09pm |
|
@MarketNotes17 $LXRX Xermelo just app'd by Euro Comm for treatment of carcinoid syndrome diarrhea September 19th 2017, 12:09pm |
|
@TheMarketsDaily Lexicon Pharmaceuticals, Inc. $LXRX Director Sam L. Barker Purchases 1,000 Shares of Stock https://t.co/IfJ7sXslWW September 19th 2017, 6:09am |
|
@WatchlistN Lexicon Pharmaceuticals, Inc. $LXRX Insider Lonnel Coats Acquires 30,000 Shares of Stock https://t.co/TxW1tmJflq September 19th 2017, 4:09am |
 |
@4thQuarterCap Added to $LXRX September 18th 2017, 9:09pm |
Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.